Medexus Pharmaceuticals Inc.
MEDXF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $108,332 | $113,054 | $108,096 | $76,701 |
| % Growth | -4.2% | 4.6% | 40.9% | – |
| Cost of Goods Sold | $51,748 | $53,540 | $48,058 | $38,774 |
| Gross Profit | $56,584 | $59,514 | $60,038 | $37,927 |
| % Margin | 52.2% | 52.6% | 55.5% | 49.4% |
| R&D Expenses | $8,260 | $8,039 | $2,943 | $5,873 |
| G&A Expenses | $28,346 | $27,857 | $36,861 | $34,521 |
| SG&A Expenses | $36,150 | $38,437 | $48,253 | $44,032 |
| Sales & Mktg Exp. | $7,804 | $10,580 | $11,392 | $9,511 |
| Other Operating Expenses | $3,951 | $2,244 | $0 | $0 |
| Operating Expenses | $48,361 | $48,720 | $51,549 | $50,303 |
| Operating Income | $8,223 | $10,794 | $7,614 | -$14,996 |
| % Margin | 7.6% | 9.5% | 7% | -19.6% |
| Other Income/Exp. Net | -$6,783 | -$10,688 | -$12,655 | $11,176 |
| Pre-Tax Income | $1,440 | $106 | -$5,041 | -$3,820 |
| Tax Expense | -$807 | $320 | -$6,262 | -$941 |
| Net Income | $2,247 | -$214 | $1,221 | -$2,879 |
| % Margin | 2.1% | -0.2% | 1.1% | -3.8% |
| EPS | 0.084 | -0.01 | 0.06 | -0.15 |
| % Growth | 985.3% | -115.8% | 140% | – |
| EPS Diluted | 0.082 | -0.01 | 0.06 | -0.14 |
| Weighted Avg Shares Out | 25,822 | 22,321 | 19,976 | 19,454 |
| Weighted Avg Shares Out Dil | 26,509 | 22,321 | 20,524 | 19,856 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $8,195 | $13,364 | $13,606 | $12,223 |
| Depreciation & Amortization | $7,178 | $5,806 | $8,046 | $7,705 |
| EBITDA | $16,813 | $19,276 | $14,646 | $15,162 |
| % Margin | 15.5% | 17.1% | 13.5% | 19.8% |